Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Avalo Therapeutics (AVTX) Divestments (2019)

Avalo Therapeutics' Divestments history spans 1 years, with the latest figure at $4.0 million for Q4 2019.

For Q4 2019, Divestments changed N/A year-over-year to $4.0 million; the TTM value through Sep 2021 reached $4.0 million, changed N/A, while the annual FY2020 figure was $12.8 million, 224.3% up from the prior year.
Divestments reached $4.0 million in Q4 2019 per AVTX's latest filing.
In the past five years, Divestments ranged from a high of $4.0 million in Q4 2019 to a low of $4.0 million in Q4 2019.